Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes

Corsi, Daniel J.; Walsh, L. J.; Weiss, Deborah Jones; Hsu, Hua‐Yi; El-Chaâr, Darine; Hawken, Steven; Fell, Deshayne B.; Walker, M W

doi:10.1097/01.aoa.0000661352.00928.f0

Cited by 35 publications

(72 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After duplicates were removed, 6542 publications were screened by title and abstract. Of these, 109 were retrieved for full‐text review and 41 studies were included in our scoping review …”

Section: Resultsmentioning

confidence: 99%

Prevalence and outcomes of prenatal recreational cannabis use in high‐income countries: a scoping review

Singh

Filion

Abenhaim

et al. 2019

BJOG

View full text Add to dashboard Cite

Background With expanding recreational cannabis legalisation, pregnant women and their offspring are at risk of potentially harmful consequences. Objectives To assess the prevalence of recreational cannabis use among pregnant women, health outcomes associated with prenatal recreational cannabis use, and the potential impact of recreational cannabis legalisation on this population. Search strategy Five databases and the grey literature were systematically searched (2000–2019). Selection criteria Human studies published in English or French reporting on the prevalence of prenatal recreational cannabis use in high‐income countries. Data collection and analysis Data on study characteristics, prenatal substance use, and health outcomes were extracted and qualitatively synthesised. Main results Forty‐one publications met our inclusion criteria. The overall prevalence of prenatal cannabis use varied substantially (min–max: 0.24–22.6%), with the greatest use in the first trimester. In the three studies with temporal data available, rates of prenatal cannabis use increased across years. Only 7/41 and 5/41 studies provided information on gestational age of exposure and frequency of use, respectively. The concomitant use of alcohol, illicit drugs, and tobacco was higher among cannabis users than nonusers. Prenatal cannabis use was associated with select neonatal, but not maternal, health outcomes. There were insufficient data to compare prenatal cannabis use between the pre‐ and post‐legalisation periods. Conclusion Cannabis use among pregnant women is prevalent and may be associated with adverse neonatal outcomes. Future studies should assess the gestational age and frequency of cannabis exposure, and usage patterns prior to and following legalisation. Tweetable abstract Women who consume cannabis during pregnancy could risk predisposing their newborns to poor birth outcomes.

show abstract

Section: Resultsmentioning

confidence: 99%

Prevalence and outcomes of prenatal recreational cannabis use in high‐income countries: a scoping review

Singh

Filion

Abenhaim

et al. 2019

BJOG

View full text Add to dashboard Cite

show abstract

“…37 In a recent registry-based study, cannabis use was associated with preterm birth and small-for-gestational-age birth. 38 Pregnant women 39 and couples 40 often prefer nonpharmacologic measures, such as CBT-I, over medications or even acupuncture. A recently published randomized controlled trial showed that pregnant women randomized to undergo CBT-I experienced a significantly greater reduction in insomnia severity and faster remission of insomnia compared with women assigned to a control intervention.…”

Section: Treatment Considerations For Insomnia In Pregnancymentioning

confidence: 99%

Sleep Pharmacotherapy for Common Sleep Disorders in Pregnancy and Lactation

Miller

Mehta

Clark-Bilodeau

et al. 2020

Chest

View full text Add to dashboard Cite

Sleep disturbances are common in pregnancy, and sleep disorders may worsen or present de novo in the course of gestation. Managing a pregnant patient is complicated by the risk of teratogenicity, pharmacokinetic changes, and the dynamic nature of pregnancy. Although nonpharmacologic interventions are likely safest, they are often ineffective, and a patient is left dealing with frustrations of the sleep disturbance, as well as the negative outcomes of poor sleep in pregnancy. As with any other condition in pregnancy, management requires an understanding of pregnancy physiology, knowledge of the impact of a given condition on pregnancy or fetal and neonatal outcomes, and an ability to weigh the risk of the exposure to an untreated, or poorly treated condition, against the risk of a given drug. In partnership with the pregnant patient or couple, options for therapy should be reviewed in the context of the impact of the condition on pregnancy and offspring outcomes, while understanding that data (positive or negative) on the impact of therapy on perinatal outcomes are lacking. This article reviews the epidemiology of sleep disorders in pregnancy, general principles of prescribing in pregnancy and lactation, and safety surrounding therapeutic options in pregnancy.CHEST 2020; 157(1): [184][185][186][187][188][189][190][191][192][193][194][195][196][197]

show abstract

“…14 Despite the increasing prevalence of prenatal cannabis exposure, there have been relatively few investigations of its association with child outcomes. These studies have found evidence linking prenatal marijuana exposure to reduced birth weight 15 and cognition 16,17 as well as heightened risk for premature birth, 18 psychopathology (i.e., psychosis, internalizing, externalizing) [19][20][21] and sleep problems 22 among children. However, there has been limited crossstudy replication, e.g., [23][24][25] and studies have typically been unable to account for other potential confounding factors (e.g., maternal education, prenatal vitamin usage, child substance use, familial risk), leaving it possible that associations between prenatal marijuana exposure and negative outcomes among children may not be independent of them.…”

Section: Introductionmentioning

confidence: 99%

Prenatal cannabis exposure and childhood outcomes: Results from the ABCD study

Paul¹,

Hatoum²,

Fine³

et al. 2019

Preprint

View full text Add to dashboard Cite

Importance: In light of increasing cannabis use among pregnant women, the Surgeon General of the United States issued an advisory against the use of marijuana during pregnancy on August 29th, 2019. Objective: To determine whether cannabis use during pregnancy is associated with adverse outcomes among offspring. Design: Cross-sectional analysis of the baseline session of the ongoing longitudinal Adolescent Brain and Cognitive Development (ABCD) study. Setting: Data were collected from 22 sites across the United States between 2016 and 2018. Participants: Children ages 9-11 (n=11,489) and their parent or caregiver. Exposure: Prenatal marijuana exposure prior to and following maternal knowledge of pregnancy. Main Outcomes and Measures: Child psychopathology symptomatology (i.e., psychotic-like experiences and internalizing, externalizing, attention, thought, and social problems), cognition, sleep, birth weight, gestational age at birth, body mass index (BMI), and brain structure (i.e., total intracranial volume, white matter volume, gray matter volume). Covariates included familial (e.g., income, familial psychopathology), pregnancy (e.g., prenatal vitamin use, whether the pregnancy was planned), and child (e.g., birth weight, substance use) variables. Results: Among 11,489 children (age 9.9±0.6 years; 47.78% female), 655 (5.70%) were prenatally exposed to cannabis in total. Marijuana use prior to (n=648; 5.64%) and following (n=242; 2.11%) maternal knowledge of pregnancy were associated with increased offspring psychopathology characteristics (i.e., psychotic-like experiences and internalizing, externalizing, attention, thought, social, and sleep problems) and BMI as well as reduced cognition, birth weight, and brain structure (i.e., total white and gray mater volumes; all psfdr<.007), but not gestational age at birth. Exposure following maternal knowledge of pregnancy remained significantly associated with psychopathology, cognition, and birth weight outcomes when including potentially confounding variables (all ps<0.046). All associations with exposure prior to maternal knowledge of pregnancy were nonsignificant when considering potentially confounding variables (all ps>0.06). Conclusions and Relevance: Prenatal cannabis exposure, and its correlated factors, may increase risk for psychopathology and reduced cognition during middle childhood as well as reduced birthweight. Consistent with recent recommendations by the Surgeon General, marijuana use during pregnancy should be discouraged.

show abstract

Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes

Cited by 35 publications

References 0 publications

Prevalence and outcomes of prenatal recreational cannabis use in high‐income countries: a scoping review

Prevalence and outcomes of prenatal recreational cannabis use in high‐income countries: a scoping review

Sleep Pharmacotherapy for Common Sleep Disorders in Pregnancy and Lactation

Prenatal cannabis exposure and childhood outcomes: Results from the ABCD study

Contact Info

Product

Resources

About